Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and paclitaxel in treating patients with metastatic or recurrent cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Completed
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of two different regimens of trastuzumab plus paclitaxel in treating wom... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/16/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Breast Cancer
Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Unknown
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy, cyclosporine, and paclitaxel follow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2013
Locations: University of California Davis Cancer Center, Sacramento, California
Conditions: Lymphoma
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
Completed
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2013
Locations: Birmingham Hematology and Oncology Associates, LLC, Birmingham, Alabama +32 locations
Conditions: Non Small Cell Lung Cancer
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel or docetaxel in treating women with stage IIIB or metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/01/2013
Locations: Montclair Regional Cancer Center, Birmingham, Alabama +31 locations
Conditions: Breast Cancer
Chemotherapeutic Agents in Brain/Breast
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Studying s... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/31/2013
Locations: Memorial Sloan Kettering, New York, New York +1 locations
Conditions: Breast Cancer, Metastatic Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with irinotecan and cisplatin followed by surgery in treating patients with stage IIIA non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2013
Locations: Yale Comprehensive Cancer Center, New Haven, Connecticut
Conditions: Lung Cancer
Abraxane/Bevacizumab
Terminated
The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This study drug combination will be given to subjects who have already been treated for their cancer with other chemotherapy, and now their cancer has become worse or has come back again. Neither one of these study drugs has been approved by the FDA for treatment in these three types of cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/18/2013
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Ovarian Cancer, Peritoneal Cancer
3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining 3-AP, cisplatin, and paclitaxel in treating patients who have advanced or metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2013
Locations: Albert Einstein Comprehensive Cancer Center, Bronx, New York +1 locations
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of combination chemotherapy plus radiation therapy with and without fluorouracil in treating patients who have cancer of the esophagus or stomach.
Gender:
ALL
Ages:
All
Trial Updated:
07/17/2013
Locations: Mobile Infirmary Medical Center, Mobile, Alabama +65 locations
Conditions: Esophageal Cancer, Gastric Cancer
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Terminated
Our hypothesis is that this study design, in which bevacizumab is added to one of six single agent chemotherapies with proven activity in metastatic breast cancer, will result in regression or stabilization of this disease in a safe and tolerable manner.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2013
Locations: Palm Beach Cancer Center Institute, West Palm Beach, Florida +3 locations
Conditions: Breast Cancer
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
Completed
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2013
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas +31 locations
Conditions: Breast Cancer